DAIICHI SANKYO, INC.
- Country
- 🇯🇵Japan
- Ownership
- Subsidiary
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $79B
- Website
- http://daiichisankyo.us
Safety Study for Intravenous (IV) AC480 (AC480IV) to Treat Advanced Solid Tumors
- First Posted Date
- 2010-11-22
- Last Posted Date
- 2015-11-01
- Lead Sponsor
- Daiichi Sankyo
- Registration Number
- NCT01245543
- Locations
- 🇺🇸
University of California San Francisco (UCSF), San Francisco, California, United States
🇺🇸South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States
Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer
- Conditions
- Non Squamous, Non-small-cell Lung Cancer
- Interventions
- First Posted Date
- 2010-11-19
- Last Posted Date
- 2021-04-06
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 1048
- Registration Number
- NCT01244191
Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma
- First Posted Date
- 2010-10-08
- Last Posted Date
- 2020-06-30
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 20
- Registration Number
- NCT01217229
- Locations
- 🇺🇸
UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Northwestern University, The Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Interventions
- First Posted Date
- 2010-09-29
- Last Posted Date
- 2021-06-16
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 222
- Registration Number
- NCT01211483
- Locations
- 🇺🇸
TRM - Oncology Research Associates, PLLC, d/b/a Pinnacle Oncology Hematology, Scottsdale, Arizona, United States
Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2010-06-23
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 24
- Registration Number
- NCT01149720
- Locations
- 🇺🇸
Premiere Oncology, Santa Monica, California, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Sarah Cannon Research Institute (SCRI), Nashville, Tennessee, United States
Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other Treatments
- First Posted Date
- 2010-05-17
- Last Posted Date
- 2013-12-03
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 21
- Registration Number
- NCT01124630
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer
- Conditions
- Advanced Non-small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2010-04-09
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 90
- Registration Number
- NCT01101334
- Locations
- 🇺🇸
DHHA, Denver, Colorado, United States
🇺🇸Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸Providence Regional Medical Center Everett, Everett, Washington, United States
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2010-02-24
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 131
- Registration Number
- NCT01075048
ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors
- Conditions
- Non-CNS Germ Cell Tumors (Seminomas and Nonseminomas)
- Interventions
- First Posted Date
- 2010-01-25
- Last Posted Date
- 2021-04-06
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 27
- Registration Number
- NCT01055067
Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors
- Conditions
- Solid Tumors
- Interventions
- Drug: Compound AC220
- First Posted Date
- 2010-01-15
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 45
- Registration Number
- NCT01049893
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States